Coherus BioSciences (CHRS) Misses Q2 EPS by 8c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.56 --0%
EPS Growth %: +23.5%
Financial Fact:
Net sales: 481.26M
Today's EPS Names:
EPAC, SAR, KRUS, More
EPS Growth %: +23.5%
Financial Fact:
Net sales: 481.26M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.34), $0.08 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $10.25 million versus the consensus estimate of $10.16 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wizz Air Holdings (WIZZ:LN) (WZZAF) PT Raised to GBP14 at Bernstein SocGen Group
- Frontier Power USA selects four battery storage projects totaling 920 MWh
- Innovative Eyewear to place smart glasses in 345 FYihealth stores
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
